Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ePAD trial of edoxaban versus clopidogrel added to aspirin after femoropopliteal endovascular intervention
NL-OMON40071Phase 2Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in arteriosclerosis obliterans comparing Edoxaban + aspirin with Clopidogrel + aspirin (2 arms). Primary endpoints: Clinically relevant bleeding and Restenosis or re-occlusion by duplex ultrasonography. Started Jul 2013; status: active, not recruiting.
02
Drugs
edoxabanclopidogrelaspirin
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on NL-OMON40071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40071.